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Abstract
IkBf is a novel member of the IkB family of NFkB regulators, which modulates NFkB activity in the nucleus, rather than
controlling its nuclear translocation. IkBf is specifically induced by IL-1b and several TLR ligands and positively regulates
NFkB-mediated transcription of genes such as IL-6 and NGAL as an NFkB binding co-factor. We recently reported that the IL-
1 family cytokines, IL-1b and IL-18, strongly synergize with TNFa for IFNc production in KG-1 cells, whereas the same
cytokines alone have minimal effects on IFNc production. Given the striking similarities between the IL-1R and IL-18R
signaling pathways we hypothesized that a common signaling event or gene product downstream of these receptors is
responsible for the observed synergy. We investigated IkBf protein expression in KG-1 cells upon stimulation with IL-1b, IL-
18 and TNFa. Our results demonstrated that IL-18, as well as IL-1b, induced moderate IkBf expression in KG-1 cells. However,
TNFa synergized with IL-1b and IL-18, whereas by itself it had a minimal effect on IkBf expression. NFkB inhibition resulted
in decreased IL-1b/IL-18/TNFa-stimulated IFNc release. Moreover, silencing of IkBf expression led to a specific decrease in
IFNc production. Overall, our data suggests that IkBf positively regulates NFkB-mediated IFNc production in KG-1 cells.
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Introduction
We previously showed that the Interleukin-1 (IL-1) family
members, IL-1b and IL-18, synergize with tumor necrosis factor-a
(TNFa) for interferon-c (IFNc) production in the human acute
myeloid leukemic KG-1 cell line [1]. IL-1b and IL-18 signal via
the Interleukin-1 receptor (IL-1R) and IL-18R, respectively, both
of which belong to the IL-1R family and the interleukin-1R/Toll-
like receptor (IL-1R/TLR) superfamily [2–5]. Members of the IL-
1R/TLR family share a cytoplasmic domain known as the Toll/
interleukin-1 receptor (TIR) domain and recruit similar adaptor
proteins, such as MyD88. Due to these and other similarities, the
signaling pathways downstream of IL-1Rs and TLRs lead to
similar outcomes, such as the activation of NFkB and MAPKs.
Although the IL-1b and TNFa receptors (IL-1R and TNFR)
belong to different families, their signaling pathways utilize similar
adaptor molecules, such as TRAFs, and lead to the activation of
NFkB and MAPKs [6–8]. Therefore, many of the genes induced
by IL-1b and TNFa overlap and the two cytokines lead to similar
biological effects. However, induction of certain genes, such as
neutrophil geletinase-associated lipocalin (NGAL)/lipocalin-2 [9],
human b-defensin 2 (hBD2) [10–14], extracellular matrix
metalloprotease 3 (MMP-3) [15] and IL-6 [16–18], is specific for
IL-1b. In the same way, expression of other genes, such as
complement factor H, is specific for the TNFa signaling pathway
[17]. Moreover, expression of the novel member of the IkB family
of NFkB regulators, IkBf, has been shown to be specific to the IL-
1R/TLR pathway (e.g. upon IL-1a/b, LPS stimulation), not the
TNFa pathway [2–5,19–24].
IkBf expression is immediately induced upon stimulation with
TLR ligands and IL-1b [19–31]. Moreover, IkBf is essential for
NFkB-mediated induction of genes encoding for proteins such as
IL-6, NGAL, hBD2, IL-12 p40, and granulocyte-macrophage
colony-stimulating factor (GM-CSF) [21,24,26,30,32–36], and for
the suppression of E-selectin expression [33]. IkBf has been shown
to positively and negatively regulate NFkB-mediated transcription
by binding to the p50 subunit of NFkB dimers
[19,21,24,26,29,30,32–34,37]. This is in contrast to other IkB
members, such as IkBa/b, which are mainly found in the cytosol
and modulate NFkB nuclear translocation. IkBf is most
homologous to the nuclear IkB protein, Bcl-3 [19,23,26,29],
which also regulates NFkB-mediated transcription as a binding co-
factor [38–50].
We recently showed that both, IL-1b and IL-18, synergize with
TNFa for IFNc production in KG-1 cells [1]. Given the
similarities between the IL-1R and IL-18R signaling pathways,
we hypothesized that a common event downstream of these two
receptors is crucial for the observed synergy between IL-1b/IL-18
and TNFa for IFNc production. Even though both, the IL-1R and
IL-18R, belong to the IL-1R/TLR superfamily, and IkBf is
specifically induced upon stimulation with several IL-1R/TLR
ligands, IkBf expression has not been investigated in response to
IL-18 stimulation. Therefore, we analyzed IkBf expression in KG-
1 cells upon IL-18 and IL-1b stimulation, and the role of IkBf in
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stimulation. Our results indicate that stimulation with IL-1b and/
or IL-18 results in moderate levels of IkBf production, while
TNFa has no effect. However, when combined with IL-1b or IL-
18, TNFa strongly enhances IkBf protein expression. Moreover,
NFkB inhibition, as well as silencing of IkBf expression, resulted
in decreased IL-1b/IL-18/TNFa-induced IFNc production.
Furthermore, IL-1R and IL-18R expression analysis indicated
that the observed synergy may take place at the receptor level in
the case of IL-18 and TNFa, but not IL-1b and TNFa combined
stimulation. In summary, our findings indicate that stimulation
with the IL-1 cytokines, IL-1b and IL-18, in combination with
TNFa results in synergistic KG-1 IFNc production in an IkBf/
NFkB dependent manner.
Methods
Reagents
Purified Escherichia coli (E. coli) LPS (serotype 0111:B4) was
obtained from Axxora (San Diego, CA) and cell culture tested
ATP disodium salt from Sigma-Aldrich (St. Louis, MO). Anti-
human IL-8 ELISA capture monoclonal Ab (clone 6217), IL-18
monoclonal Ab (clone 159-12B), IL-18 receptor (IL-18R) mono-
clonal Ab (clone 70625), and human rIL-1b, rIL-18 and rIL-8
were purchased from R&D Systems (Minneapolis, MN). An IkBa
polyclonal Ab was obtained from Upstate (Billerica, Massachu-
setts), actin monoclonal Ab (clone C4) from MP Biomedicals
(Solon, OH), p50 monoclonal (clone E-10) Ab and p65 polyclonal
Ab from Santa Cruz (Santa Cruz, CA), lamin B1 polyclonal Ab
from Abcam (Cambridge, MA), TNFa capture monoclonal Ab
(clone 2C8) from Advanced Immunochemical (Long Beach, CA),
IL-8 ELISA detection polyclonal Ab from Endogen (Rockford,
IL), rTNFa from Knoll Pharmaceuticals (Whippany, NJ),
Interleukin-1 receptor antagonist (IL-1ra) from Amgen (Thousand
Oaks, CA), and IFNc and IL-6 ELISA kits from eBioscience (San
Diego, CA). Rabbit anti-serum against IkBf and IL-1b and pre-
immune serum were developed in our laboratory. The NFkB
inhibitor, JSH23, was purchased from Calbiochem (San Diego,
CA). A mixture of three different small interfering RNA (siRNA)
oligonucleotides against IkBf and three different scrambled siRNA
oligonucleotides were purchased from Dharmacon RNA Tech-
nologies (Lafayette, CO). The cell line nucleofector kit R was
purchased from Amaxa (Gaithersburg, MD).
Cell Culture
KG-1 cells (American Type Culture Collection, ATCC;
Manassas, VA) were maintained in RPMI 1640 (Mediatech Inc,
Herndon, VA), supplemented with 20% FBS (Atlas Biologicals,
Fort Collins, CO) and 1% penicillin/streptomycin in a 37uC
humidified incubator with 5% CO2. Peripheral blood monocytes
were isolated from human blood by density gradient centrifugation
using lymphocyte separation media (Cell Grow, Media Tech,
Herndon, VA) followed by CD14 positive selection (Miltenyi
Biotec, Auburn, CA), which yields.95% purity as determined by
FACS. Isolated monocytes were cultured at 10
6/ml or at
12.5610
6/ml in RPMI 1640 (Cambrex, East Rutherford, New
Jersey), supplemented with 5% FBS (,0.0005 EU/ml) (HyClone,
Logan, UT) and 1% penicillin/streptomycin (GIBCO, Grand
Island, NY), in a 37uC humidified incubator with 5% CO2.
Monocytes were stimulated, or not, with E. coli LPS (10 ng/ml)
for 4 h and ATP (5 mM) for the last 15 min of LPS stimulation, or
with LPS or ATP alone. The supernatants (conditioned media)
from monocytes cultured at 10
6/ml were harvested by centrifu-
gation (5 min; 3 600 rpm) and used to stimulate KG-1 cells.
KG-1 cells were plated at a final cell density of 10
6/ml and
incubatedwithtestsamples(monocyteconditionedmedia,1/3ofthe
final volume) or recombinant proteins (10 ng/ml each). In selected
experiments, neutralizing agents for IL-1b (IL-1b Ab – clone 2805,
IL-1ra), IL-18 (IL-18 Ab – clone 125-2H, or IL-18R Ab – clone
70625), and/or TNFa (TNFa Ab – clone 2C8) were used at the
indicated concentrations to neutralize the activities of rIL-18, rIL-1b
and/or rTNFa, or the same endogenous cytokines present in the
monocyte conditioned media, prior to incubation with KG-1 cells.
Alternatively, the neutralizing agents, IL-1ra and IL-18R Ab, were
usedto neutralizeIL-18 orIL-1 receptorspriortoaddition of rIL-18,
rIL-1b, or monocyte conditioned media, to the KG-1 cells. KG-1
supernatants and cells were harvested at various time points for
subsequent ELISA and Western blot analysis. In selected experi-
ments, cells were treated with the NFkBi n h i b i t o r ,J S H - 2 3( 3 0mM)
(an NFkB nuclear translocation inhibitor), in combination with rIL-
1b, rIL-18 and rTNFa for 24 h. KG-1 cells were harvested at 12 h
for subsequent nuclear extraction and Western blot analysis. KG-1
supernatants were harvested at 24 h for IL-6 and IFNc ELISA.
Western blotting
KG-1 cells were lysed in a 60 mM Tris-HCl (pH 6.8), 2% SDS
buffer. Total cell extracts were sonicated and spun (5 min; 10
000 rpm, R.T.) to remove cell debris. KG-1 nuclear/cytosolic
extracts were also analyzed by Western blotting. Protein concen-
tration in total, nuclear or cytosolic extracts was estimated using the
Bio-Rad Dc protein Lowry assay (Bio-Rad). Samples were boiled in
Laemmli’s buffer for 5 min or heated at 70uC for 10 min in
NuPAGE Sample Reducing Agent (Invitrogen). 10–40 mg of total
protein were loaded per well on pre-cast 10% Tris-Glycine or 7%
Tris-Acetate SDS-PAGE gels and transferred to a PVDF or
nitrocellulose membrane. Membranes were blocked with 10%
nonfat milk (Carnation, Nestle) in 25 mM Tris-HCl (pH 7.5),
150 mM NaCl, and 0.05% Tween for 1 h at R.T. The membranes
were probed with the indicated primary Abs, followed by
peroxidase-conjugated secondary antibodies. Protein bands were
visualized by chemiluminescence (GE Healthcare).
ELISA
Sandwich ELISAs were used to measure cytokine release in the
supernatants of KG-1 cells.
Flow Cytometry
KG-1 cells (10
6/ml) were stimulated, or not, with the indicated
combinations of rIL-1b, rIL-18 and rTNFa (10 ng/ml each) for
24 h. Cells were Fc-blocked by treating with 1 mg of human IgG/
10
5 for 15 min at R.T. Cells (10
5/25 ml*reaction) were transferred
to a 5 ml tube. Phycoerythrin (PE)-conjugated anti-IL-18Ra or
fluorescein (FITC)-conjugated anti-IL-1R1 reagent (10 ml of each
per reaction) were added to the cells. Cells were incubated for
30 min at 4uC, washed twice with 16PBS and re-suspended in
16PBS (10
5/200 ml) for flow cytometric analysis. As controls, cells
were also treated with phycoerythrin-labeled murine IgG1 and
fluorescein-labeled goat IgG.
Nuclear/Cytosolic extraction
KG-1 cells (10
6/ml) were stimulated, or not, with rIL-1b,r I L - 1 8 ,
rTNFa (10 ng/ml each), or a combination of this cytokines for the
indicated time points. Cells were washed twice in 16PBS and gently
re-suspended in cold Buffer A (10 mM HEPES, pH 7.9; 10 mM
KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM dithiothreitol [DTT];
16Complete Mini protease inhibitor cocktail, Roche) at 400 ml/
0.521610
6 cells. Cells were allowed to swell for 15 min. 10%
IkBf Regulates IFNc
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Sampleswerevortexedfor10 secandcentrifugedfor30 sec(4uC,13
200 rpm). Supernatants containing cytosolic contents were trans-
ferred to fresh tubes containing an equal volume of Buffer B (10 mM
Tris-HCl, pH 7.5; 7 M urea; 1% SDS; 0.3 M NaAc; 20 mM
EDTA) and stored immediately at 220uC. The pellets containing
the nuclear contents were re-suspended in cold Buffer C (20 mM
HEPES, pH 7.9; 0.4 M NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM
dithiothreitol (DTT); 16Complete Mini protease inhibitor cocktail,
Roche) at 50 ml/0.521610
6 cells. The samples were vigorously
shook for 15 min at 4uC on a shaking platform and then centrifuged
for 5 min (4uC, 13 200 rpm). The supernatants with the nuclear
contents were stored at 220uC. Nuclear and cytosolic extracts were
subsequently analyzed for protein concentration using the Bio-Rad
Dc protein Lowry assay (Bio-Rad). Nuclear and cytosolic extracts
were then prepared for Western blot analysis.
Small interfering RNA
KG-1 cells (2610
6/ml) were nucleofected following the protocol
for KG-1 cell nucleofection provided with the cell line nucleofector
kit R from Amaxa (Gaithersburg, MD) with a mixture of 3
different small interfering RNA (siRNA) oligonucleotides against
IkBf or 3 different scrambled siRNA oligonucleotides (3 mg per
2610
6 cells). After 2 h, cells were stimulated with a combination of
rIL-1b, rIL-18 and rTNFa (10 ng/ml each). Cells and superna-
tants were harvested at 24 h for subsequent RNA and protein
analysis (qPCR and Western blot, respectively).
Quantitative PCR (qPCR)
KG-1 cells (10
6/ml) were lysed in TRIzol reagent (Invitrogen
Life Technologies) and mRNA was extracted and converted to
cDNA using the Thermoscript RT-PCR system (Invitrogen Life
Technologies). qPCR was performed using specific primers for
IFNc, IL-6 and IL-8. Values were normalized to two house-
keeping genes, CAP-1 and GAPDH.
Statistical analysis
Data are presented mean6S.E.M. from$3 independent
experiments. Comparisons were done by paired t-test with
p,0.05 defined as statistically significant.
Results
IL-1b and IL-18, but not TNFa, induce IkBf protein
expression in KG-1 cells
We have recently demonstrated that IL-1R and IL-18R agonists
synergize with TNFa for IFNc production in KG-1 cells [1]. The
IL-1R, IL-18R and TLRs all belong to the IL-1R/TLR
superfamily [2]. Because expression of the IkB protein family
member, IkBf, is known to be induced downstream of the IL-1R
and TLRs [19–31], we chose to evaluate its potential role in IFNc
production in response to IL-1b/IL-18 and TNFa combined
stimulation. We analyzed induction of IkBf protein expression in
response to IL-1b and IL-18, with the idea that IkBf may be the
common factor downstream of the IL-1R and IL-18R, responsible
for the observed synergy between IL-1b/IL-18 and TNFa for
IFNc production [1].
In this context, KG-1 cells were stimulated with rIL-1b, rIL-18
and rTNFa for various time points, with and without co-addition
of IL-1ra or IL-18 Ab. Total cell extracts were analyzed for IkBf
protein expression by Western blotting. Results indicated that both
rIL-1b and rIL-18, but not rTNFa, induced IkBf expression in
KG-1 cells (Fig. 1A–C). The lack of rTNFa-mediated IkBf
expression was not due to lack of biological activity of rTNFa,a s
judged by the modulation (degradation and de novo protein
synthesis) of IkBa expression upon rTNFa stimulation (Fig. 1C).
The finding that IL-1b, as well as IL-18, both induce IkBf protein
expression supports the hypothesis that IkBf may be the common
factor downstream of the IL-1R and IL-18R that allows for
synergy between IL-1 cytokines (IL-1b and IL-18) and TNFa for
IFNc production in KG-1 cells.
TNFa enhances IL-1b/IL-18-mediated IkBf expression.
Stimulation with TNFa alone does not lead to IkBf expression
(Fig. 1C) [19–21,24]. However, TNFa has been shown to induce
IkBf transcription to a greater extent than IL-1b and LPS [20]. In
contrast, upon actinomycin D treatment, the half-life of ectopically
expressed IkBf mRNA was prolonged with IL-1b and LPS, but
unaffected by TNFa. Therefore, even though TNFa has strong
IkBf transcriptional activity, IL-1/LPS may provide additional
mRNA stabilization (absent with solo TNFa stimulation) leading
to subsequent protein expression. Based on this information, we
Figure 1. IkBf protein expression in KG-1 cells in response to IL-1b, IL-18 and TNFa stimulation. KG-1 cells (10
6/ml) were stimulated with
rIL-1b (A), rIL-18 (B), or rTNFa (C) (10 ng/ml each) for the indicated time points. At selected time points, the cells were incubated with rIL-1b and rIL-
18 in the presence of IL-1ra (100 mg/ml) or IL-18 Ab (2 mg/ml), respectively. Protein-matched total cell extracts were analyzed by Western blotting
using anti-serum against IkBf, IkBa Ab and actin Ab. Results are representative of at least 3 separate experiments.
doi:10.1371/journal.pone.0006776.g001
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IkBf protein expression by providing strong transcriptional
activation, even though by itself it does not lead to IkBf protein
expression.
To test this hypothesis, KG-1 cells were stimulated with rTNFa
alone and in combination with rIL-1b, rIL-18, or both, for 8 and
24 h. Total cell extracts were analyzed for IkBf protein expression
by Western blotting. Recombinant TNFa enhanced rIL-1b- and
rIL-18-mediated IkBf protein expression at both time points
(Fig. 2). We then analyzed the kinetics of KG-1 IkBf protein
expression in response to different combinations of rIL-1b, rIL-18
and rTNFa, with and without co-addition of IL-1ra, IL-18R Ab,
TNFa Ab, or different combinations of these neutralizing agents.
Interestingly, IkBf protein expression followed an oscillating
pattern (Fig. 3), which is typical of IkB proteins, such as IkBa.
Moreover, it was evident that the observed induction of IkBf
protein upon stimulation with rTNFa combined with rIL-1b, rIL-
18, or both, was in part due to rTNFa, since the induction was
only partially suppressed with a TNFa neutralizing Ab (Fig. 3B
and C). The remaining IkBf protein expression after TNFa
neutralization was likely due to IL-1b and/or IL-18. As expected,
neutralization with IL-1ra or IL-18R Ab, resulted in complete
inhibition of IkBf expression, indicating that TNFa by itself has
no IkBf inducing activity. Interestingly, rIL-1b, rIL-18 or the
combination of these cytokines (at a dose of 10 ng/ml) results in
minimal amounts of IFNc production by KG-1 cells, despite their
ability to induce IkBf protein expression [1]. Therefore, the levels
of IL-1b/IL-18-induced IkBf protein may either not be sufficient
for significant IFNc production (in the absence of TNFa
stimulation), or may require an additional TNFa-induced factor
for activation of the IFNc promoter.
Figure 2. TNFa enhances IL-1b/IL-18-induced IkBf protein
expression in KG-1 cells. KG-1 cells (10
6/ml) were stimulated with
rIL-1b, rIL-18, rTNFa (10 ng/ml each), or different combinations of these
cytokines for 8 and 24 h. Protein-matched total cell extracts were
analyzed by Western blotting using anti-serum against IkBf and actin
Ab.
doi:10.1371/journal.pone.0006776.g002
Figure 3. The synergistic effect of TNFa and IL-1b/IL-18 on IkBf protein expression is partially suppressed with a TNFa-specific Ab,
but completely blocked with IL-1b and/or IL-18 neutralization. KG-1 cells (10
6/ml) were stimulated with rIL-1b, rIL-18, rTNFa (10 ng/ml each)
(A), or the indicated combinations of these cytokines (B and C) for the indicated time points. At selected time points, the cells were incubated with
the recombinant proteins in the presence of IL-1ra (100 mg/ml), IL-18R Ab (10 mg/ml), TNFa Ab (10 mg/ml), or different combinations of these
neutralizing agents. Protein-matched total cell extracts were analyzed by Western blotting using anti-serum against IkBf and actin Ab. Results are
representative of at least 3 separate experiments.
doi:10.1371/journal.pone.0006776.g003
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monocytes induces IkBf expression in an IL-1b-
dependent, but IL-18-independent manner
We have recently shown that the conditioned media from LPS/
ATP-treated monocytes induces IFNc release by KG-1 cells and
that this induction is due to the synergistic effect of IL-1b and
TNFa, and independent of IL-18 [1]. Herein, we incubated KG-1
cells with conditioned media from LPS/ATP-stimulated mono-
cytes for various time points, with and without co-addition of IL-
1ra, IL-18R Ab, TNFa Ab, or different combinations of these
neutralizing agents, and analyzed IkBf protein expression. The
monocyte conditioned media induced IkBf protein expression in
an IL-1b-dependent, but IL-18-independent manner (Fig. 4). This
finding correlates with our previous observation that endogenous
IL-18 present in the conditioned media from LPS/ATP-
stimulated monocytes does not induce IFNc production by KG-
1 cells [1]. The lack of IL-18 IFNc inducing activity in the
supernatants of LPS/ATP-stimulated monocytes may be due to
low levels of IL-18 being released or to IL-18 being bound to its
biological inhibitor, IL-18BP [1].
TNFa upregulates IL-18R, not IL-1R expression
TNFa has been shown to upregulate expression of the IL-18R in
KG-1 cells [51–57]. Therefore, TNFa may synergize with IL-1b in
a similar manner for IkBf and IFNc production – by upregulating
surface expression of the IL-1R. In order to explore this possibility,
KG-1 cells were treated with the indicated combinations of rIL-1b,
rIL-18 and rTNFa for 24 h. TNFa treatment resulted in
upregulation of IL-18R, not IL-1R expression, as determined by
flow cytometry (Fig. 5). Therefore, a signaling event(s) downstream
of the IL-1R and IL-18R, rather that TNFa-mediated receptor
upregulation, is likely to be crucial forthe observed synergy between
IL-1 cytokines and TNFa for IkBf and IFNc production.
Moreover, the greater IFNc production in response to rIL-18 in
combination with rTNFa, compared to rIL-1b in combination with
rTNFa [1], may be explained by additional TNFa-mediated
upregulation of the IL-18R.
IkBf protein localizes to the nucleus
IkBf protein has been shown to localize to the nucleus in most
cell types [19,23,26,28,34]. However, IkBf has also been shown to
localize to the cytoplasm in B cell rich regions of immune organs,
such as lymphoid follicles in the spleen [28]. In order to confirm
the cellular localization of IkBf protein in the KG-1 cell line, cells
were stimulated with rIL-1b, rIL-18, rTNFa and different
combinations of these cytokines for 8 h and harvested for cytosol
and nuclear extraction. Results demonstrate that IkBf protein
localizes predominantly to the nucleus of KG-1 cells (Fig. 6),
consistent with its role as a co-factor for NFkB-mediated
transcription.
NFkB inhibition leads to decreased IFNc and IL-6 release
IkBf has been shown to act as an NFkB binding co-factor by
associating with the p50 NFkB subunit. Therefore, we decided to
test whether IFNc release in KG-1 cells in response to IL-1b, IL-
18 and TNFa combined stimulation is NFkB dependent. KG-1
cells were incubated with an inhibitor of NFkB nuclear
Figure 4. The conditioned media from LPS/ATP-stimulated
monocytes induces IkBf expression in an IL-1b/TNFa-depen-
dent, but IL-18-independent manner. KG-1 cells (10
6/ml) were
incubated with conditioned media from monocytes (10
6/ml) that were
stimulated with LPS (10 ng/ml, 4 h) and ATP (5 mM, last 15 min) for the
indicated time points. For selected time points, the cells were incubated
with the conditioned media in the presence of IL-1ra (100 mg/ml), IL-
18R Ab (10 mg/ml), TNFa Ab (10 mg/ml), or different combinations of
these neutralizing agents. Protein-matched total cell extracts were
analyzed by Western blotting using anti-serum against IkBf and actin
Ab. Results are representative of 3 separate experiments.
doi:10.1371/journal.pone.0006776.g004
Figure 5. Effect of TNFa treatment on KG-1 IL-18R and IL-1R surface expression. KG-1 cells (10
6/ml) were incubated with the indicated
combinations of rIL-1b, rIL-18, rTNFa (10 ng/ml each) for 24 h. Cells were stained with IL-18R-PE and IL-1R-FITC followed by flow cytometry analysis.
Results are representative of 3 separate experiments.
doi:10.1371/journal.pone.0006776.g005
IkBf Regulates IFNc
PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6776translocation followed by IL-1b, IL-18 and TNFa combined
stimulation. Western blot analysis with nuclear extracts indicated a
reduction in p50 and p65 nuclear localization, indicative of a
decrease in NFkB activity (data not shown). Moreover, IL-6 and
IFNc release were significantly reduced with NFkB inhibition
(Fig. 7). Therefore, IkBf may regulate IFNc release in KG-1 cells
in response to IL-1b, IL-18 and TNFa combined stimulation by
acting as a co-factor for NFkB-mediated transcription.
Silencing of IkBf suppresses IFNc and IL-6, not IL-8
production
IkBf has been shown to either negatively or positively regulate
NFkB activity depending upon the context. Genes, such as E-
selectin, are negatively regulated [33], whereas genes such as IL-6
and NGAL, are positively regulated [21,24,26,32–35]. Because IL-
1b/IL-18 or TNFa blockade inhibits both IkBf protein expression
and IFNc production in KG-1 cells, we hypothesized that IkBf
positively regulates IFNc production.
In order to test this hypothesis, KG-1 cells were nucleofected with a
mixture of 3 different small interfering RNA (siRNA) oligonucleotides
against IkBf or 3 different scrambled siRNA oligonucleotides. Cells
were then stimulated with a combination of rIL-1b,r I L - 1 8a n d
rTNFa. Western blot analysis indicated a reduction in IkBf protein
expression with anti-IkBf siRNA delivery (Fig. 8). In order to
determine the effect of IkBf silencing on IFNc protein production, we
measured IFNc mRNA levels and protein release in KG-1 cells upon
rIL-1b,r I L - 1 8a n dr T N F acombined stimulation (Fig. 9). As a positive
Figure 6. IkBf mainly localizes to the nucleus. KG-1 cells (10
6/ml) were stimulated with rIL-1b, rIL-18, rTNFa (10 ng/ml each), or different
combinations of these cytokines for 8 h. Cells were harvested for subsequent cytosol and nuclear extraction. Protein-matched nuclear and cytosolic
extracts were then analyzed by Western blotting with anti-serum against IkBf, laminB1 Ab (nuclear marker) and IL-1b Ab (cytosolic marker). Results
are representative of 3 separate experiments.
doi:10.1371/journal.pone.0006776.g006
Figure 7. NFkB inhibition results in decreased IFNc and IL-6
release. KG-1 cells (10
6/ml) were incubated with the NFkB inhibitor,
JSH23 (30 mM), and subsequently stimulated with a combination of rIL-
1b, rIL-18 and rTNFa (10 ng/ml each). Supernatants were harvested
after 24 h and analyzed for cytokine release by IL-6 and IFNc ELISAs.
Results are shown as mean6S.E.M. *, p,0.05; **, p,0.005 (n=3).
doi:10.1371/journal.pone.0006776.g007
Figure 8. Silencing of IkBf expression. KG-1 cells (2610
6/ml) were
nucleofected with a mixture of 3 different small interfering RNA (siRNA)
oligonucleotides against IkBf or 3 different scrambled siRNA oligonu-
cleotides. After 2 h, cells were stimulated with a combination of rIL-1b,
rIL-18 and rTNFa (10 ng/ml each) for the indicated time points. Protein-
matched total cell extracts were analyzed by Western blotting using
anti-serum against IkBf and actin Ab. Results are representative of 5
separate experiments.
doi:10.1371/journal.pone.0006776.g008
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cytokine has been shown to be positively regulated by IkBf
[21,26,32,34,35]. As a negative control, we measured IL-8 mRNA
and protein levels,which have been shownnot toberegulatedby IkBf
[24,33]. Results indicated that the mRNA and protein levels of IFNc
and IL-6, but not IL-8, were significantly reduced with anti-IkBf
siRNA delivery (Fig. 9). These results implicate a role for IkBf as a
positive regulator of IFNc production.
Discussion
Regulation of IFNc gene transcription involves the action of
many different transcripition factors including STATs, AP-1,
GATA-3, NFAT, T-bet, Eomesodermin, NFkB, NFAT, T-bet,
YY-1, DREAM, ERM and SMADs. In most cases, multiple
signals synergize for IFNc production via induction of different
transcription factors that act in concert to induce gene expression
[58–61]. The combination of IL-12 and IL-18 is the most well-
known example of synergy between two cytokines for IFNc
production in T cells, NK/NKT cells, B cells, macrophages and
dendritic cells [62–70]. Synergy between IL-12 and IL-18 occurs
not only at the transcription factor level via STAT4 and AP-1
activation, respectively, but also at the receptor level, with both
cytokines upregulating cell surface expression of each other’s
receptors. Synergy for IFNc production has also been observed
with the combination of receptor crosslinking and cytokine
Figure 9. Silencing of IkBf expression suppresses IFNc and IL-6, not IL-8, mRNA and protein production. KG-1 cells (2610
6/ml) were
nucleofected with a mixture of 3 different small interfering RNA (siRNA) oligonucleotides against IkBf or 3 different scrambled siRNA
oligonucleotides. After 2 h, cells were stimulated with a combination of rIL-1b, rIL-18 and rTNFa (10 ng/ml each) for 24 h. Cells were lysed for mRNA
extraction. Messenger RNA (mRNA) was converted to cDNA, followed by quantitative PCR (qPCR) using primers specific for IFNc (A), IL-6 (B) and IL-8
(C). Supernatants were harvested and analyzed for cytokine release by IFNc (D), IL-6 (E) and IL-8 (F) ELISA. Results are shown as mean6S.E.M. *,
p,.05; **, p,0.005 (A, B and C,n=3 )( D, E and F, n=5).
doi:10.1371/journal.pone.0006776.g009
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receptor crosslinking and IL-12 or IL-18 synergistically enhance
IFNc production in NK cells via the p38 MAP kinase and the
ERK-dependent signal transduction pathways [71].
In general, IL-12 and IL-18 require each other for IFNc gene
expression. However, at high doses (50 ng/ml), IL-18 alone can
induce IFNc production in the human acute myeloid leukemic
KG-1 cell line [1,24]. KG-1 cells have been widely used to study
IL-18-mediated signaling events leading to IFNc expression. The
responsiveness of KG-1 cells to IL-18 (in absence of IL-12) is partly
due to constitutive expression of both chains of the IL-18R
[72,73], whereas primary NK and T cells require IL-12
stimulation for expression of the binding chain of the IL-18R
[70,74–77].
NFkB has been shown to regulate the expression of many pro-
inflammatory genes, IFNc being no exception. Two putative
NFkB binding sites have been identified in the IFNc promoter
region (kBB site and CD28RE) and one in the first intron (C3)
[78]. The requirement for NFkB in IFNc gene expression appears
to be contingent on the cell type and the specific stimulus. IL-18
signaling via the IL-18R leads to NFkB activation [78–82].
Moreover, stimulation of KG-1 cells with high doses (50 ng/ml) of
IL-18 leads to IFNc production in an NFkB-dependent manner
[78].
We have previously described a novel synergistic role for the
members of the IL-1 family, IL-1b and IL-18, in combination with
TNFa in IFNc production in KG-1 cells [1]. Importantly, at the
dose of 10 ng/ml, the individual cytokines induced only minimal
amounts of IFNc release. Given the striking similarities between
the IL-1b and IL-18 signaling pathways, we proposed that a
common factor downstream of the IL-1R and IL-18R is
responsible for the observed synergy between IL-1b/IL-18 and
TNFa. The latter is supported by the fact that induction of the
IFNc promoter is generally mediated by multiple signals leading to
activation of multiple transcription factors that synergistically
induce IFNc gene expression [58–61].
The novel member of the IkB family of NFkB regulators, IkBf,
is known to be induced by IL-1R/TLR ligands. Moreover, even
though the TNFR signaling pathway shares some similarities with
the IL-1R/TLR pathway, such as the use of TRAF adaptor
molecules, TNF signaling alone does not result in IkBf protein
expression [2–5,19–24]. Although IL-18 signals via a member of
the IL-1R family, it has never been tested as an inducer of IkBf
expression. We have shown for the first time that IL-18 stimulation
also leads to IkBf protein expression in KG-1 cells.
IkBf has been shown to positively regulate NFkB-mediated
transcription of secondary response genes such as IL-6 and NGAL,
as a co-factor binding to the p50 NFkB subunit
[21,24,26,32,33,35]. Moreover, NFkB has been shown to play
an important role as a positive regulator of IFNc gene expression
in thymocytes, peripheral blood T lymphocytes and KG-1 cells
[66,78,83]. Therefore, we hypothesized that IkBf may be the
common factor downstream of the IL-1R and IL-18R pathways,
which allows for synergy between IL-1 cytokines and TNFa for
IFNc production in KG-1 cells.
Interestingly, we observed that TNFa enhanced IL-1b/IL-18-
mediated IkBf protein expression, even though by itself it had
n o te f f e c to nI kBf protein expression. However, TNFa,I L - 1 b
and LPS have all been shown to induce IkBf mRNA
transcription in NIH3T3 and A549 cells [20]. Importantly,
TNFa stimulation alone results in strong activation of the IkBf
promoter without subsequent protein expression. Moreover,
nuclear run-on analysis in NIH3T3 cells also indicates that
TNFa is a stronger transcriptional activator of the IkBf gene,
compared to IL-1b or LPS. Furthermore, decay analysis of
ectopically expressed IkBf mRNA upon actinomycin D treat-
ment, indicates that degradation of IkBf mRNA is delayed by IL-
1b and LPS stimulation, but not by TNFa stimulation.
Moreover, the N-terminal half, not the C-terminal half, of the
IkBf ORF confers IL-1/LPS-mediated IkBf mRNA stabiliza-
tion. Therefore, the specificity of IL-1/LPS stimulus for IkBf
mRNA and protein induction is most likely at the post-
transcriptional level and due to stabilization of IkBf mRNA. A
cis-element in the N-terminal half of the IkBf gene appears to be
crucial for this stabilization [20].
In support of the latter findings, the NGAL promoter has been
shown to be specifically induced by IL-1b, not by TNFa
[9,21,84,85]. NGAL promoter activity requires NFkB activation
and an intact NFkB binding site [24]. Even though IL-1b and
TNFa, both induce NFkB nuclear translocation and recruitment
to the NGAL promoter, only IL-1b is able to induce NGAL
expression. IkBf has been shown to be the co-factor which allows
NFkB to mediate NGAL gene expression downstream of the IL-
1R/TLR signaling pathway [24]. The latter was shown by IkBf
over expression in A549 cells, which rescued TNFa-induced
NGAL expression. The same may apply to expression of the IL-6
gene, which at least in the KG-1 cell line (data not shown) and
other cell types [16–18], is specific to IL-1b, not TNFa
stimulation, and to other genes specifically induced downstream
of the IL-1R/TLR pathway. As an additional example, hBD2 is
also stimulated by IL-1b, but not TNFa stimulation in human
keratinocytes [9,84] and A549 cells [24]. Moreover, siRNA
experiments have shown that IkBf is critical for IL-1b mediated
hBD2 mRNA expression in A549 cells [24].
Based on this information, we conclude that while IL-1b and
IL-18 may provide the signal(s) required for IkBf transcriptional
activation, mRNA stabilization and subsequent IkBf protein
expression, TNFa may enhance IL-1b/IL-18-mediated IkBf
expression by providing strong transcriptional activation of the
IkBf gene. Moreover, TNFa stimulation of KG-1 cells provides
robust binding of the p50 and p65 NFkB subunits to EMSA
probes containing the NFkB binding sites present in the IFNc
promoter and first intron (data not shown), compared to weaker
binding provided by IL-1b and IL-18. Therefore, robust NFkB
activation provided by TNFa may also result in increased IFNc
gene expression since IkBf regulates transcription as a co-factor
for NFkB and KG-1 IFNc production in response to IL-1/TNFa
combined stimulation is NFkB dependent (Fig. 7). Thus, the
synergy between IL-1b/IL-18 and TNFa may be due to their
combined effects on IkBf expression, as well as on NFkB
activation. Alternatively, other transcription factors induced by
TNFa may synergize with IkBf/NFkB for IFNc gene expression.
Receptor expression analysis indicated that TNFa-mediated
upregulation of IL-1/IL-18R expression did not account for the
synergy between these cytokines for IkBf production.
In summary, we have shown a positive role for IkBf on IFNc
production in response to IL-1b, IL-18 and TNFa combined
stimulation in KG-1 cells. This regulation is most likely dependent
on the ability of IkBf to regulate NFkB mediated transcription of
the IFNc gene. This finding represents a new addition to the
complex and continuously growing literature on the regulation of
IFNc expression.
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